Eli Lilly EPS - Earnings per Share 2010-2024 | LLY

Eli Lilly annual and quarterly earnings per share history from 2010 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Eli Lilly EPS for the quarter ending March 31, 2024 was $2.48, a 66.44% increase year-over-year.
  • Eli Lilly EPS for the twelve months ending March 31, 2024 was $6.79, a 7.95% increase year-over-year.
  • Eli Lilly 2023 annual EPS was $5.8, a 15.94% decline from 2022.
  • Eli Lilly 2022 annual EPS was $6.9, a 12.75% increase from 2021.
  • Eli Lilly 2021 annual EPS was $6.12, a 9.87% decline from 2020.
Eli Lilly Annual EPS
2023 $5.80
2022 $6.90
2021 $6.12
2020 $6.79
2019 $8.89
2018 $3.13
2017 $-0.19
2016 $2.58
2015 $2.26
2014 $2.23
2013 $4.32
2012 $3.66
2011 $3.90
2010 $4.58
2009 $3.94
Eli Lilly Quarterly EPS
2024-03-31 $2.48
2023-12-31 $2.42
2023-09-30 $-0.06
2023-06-30 $1.95
2023-03-31 $1.49
2022-12-31 $2.14
2022-09-30 $1.61
2022-06-30 $1.05
2022-03-31 $2.10
2021-12-31 $1.88
2021-09-30 $1.22
2021-06-30 $1.53
2021-03-31 $1.49
2020-12-31 $2.31
2020-09-30 $1.33
2020-06-30 $1.55
2020-03-31 $1.60
2019-12-31 $1.77
2019-09-30 $1.37
2019-06-30 $1.44
2019-03-31 $4.31
2018-12-31 $1.10
2018-09-30 $1.12
2018-06-30 $-0.25
2018-03-31 $1.16
2017-12-31 $-1.57
2017-09-30 $0.53
2017-06-30 $0.95
2017-03-31 $-0.10
2016-12-31 $0.73
2016-09-30 $0.73
2016-06-30 $0.71
2016-03-31 $0.41
2015-12-31 $0.45
2015-09-30 $0.75
2015-06-30 $0.56
2015-03-31 $0.50
2014-12-31 $0.40
2014-09-30 $0.47
2014-06-30 $0.68
2014-03-31 $0.68
2013-12-31 $0.68
2013-09-30 $1.11
2013-06-30 $1.11
2013-03-31 $1.42
2012-12-31 $0.74
2012-09-30 $1.18
2012-06-30 $0.83
2012-03-31 $0.91
2011-12-31 $0.77
2011-09-30 $1.11
2011-06-30 $1.07
2011-03-31 $0.95
2010-12-31 $1.05
2010-09-30 $1.18
2010-06-30 $1.22
2010-03-31 $1.13
2009-12-31 $0.82
2009-09-30 $0.86
2009-06-30 $1.06
2009-03-31 $1.20
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $731.812B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01